Business Wire

CA-HAI-ROBOTICS/SKECHERS

20.2.2024 12:01:30 CET | Business Wire | Press release

Share
Skechers Launches High-Tech Warehouse With Hai Robotics' Automated Goods-to-Person System

Skechers USA, a leading global footwear and apparel company, turns to Hai Robotics ("Hai"), a leading global provider of Automated Storage and Retrieval Systems (ASRS), as they launch their new distribution center in Minato City, Tokyo, Japan. Using Hai’s automated goods-to-person system, Skechers is maximizing warehouse operational efficiency, fulfillment speed, and order accuracy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240220854625/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

A Hai Robotics Autonomous Case-handling Mobile Robot (ACR), one of 69 that pick and transport containers to fulfill orders within Skechers’ distribution center. (Photo: Business Wire)

Hai’s solution was chosen for its ability to condense storage — minimizing real estate needed — and easily adapt to changing demand, resolve labor shortage issues, and support long-term business growth.

Supported by material handling consulting company MHE Solutions, Inc., Skechers built their new facility to keep up with rapidly growing demand in the Japanese market and to advance operations that had historically relied on manually laborious tasks. Manual picking processes had been the standard to fulfill orders, but managing staff shortages coupled with expanding SKU variety contributed to high operating costs with limited outbound picking efficiency and speed. After evaluating several automation providers, Skechers ultimately determined Hai Robotics’ HaiPick System was the ideal solution for dependable and effective automated order fulfillment.

The HaiPick System is dense, adaptable to changes in consumer demand, and easily expandable as operations grow. It seamlessly integrated with other technologies in the facility to help Skechers quickly respond to customer orders. The system has also extended employee productivity while reducing physical demand on staff, helping to alleviate disruption from labor shortages.

Within Skechers’ facility, the HaiPick System covers 139,705 square feet and is operated by 69 HaiPick Autonomous Case-handling Mobile Robots (ACRs), which are integrated with Manhattan Associates' cloud-native warehouse management system (WMS). ACRs are highly intelligent, tall pieces of equipment that autonomously navigate narrow aisles of an ASRS constructed of almost any industry-standard racking or shelving with a vertical reach extending up to 32 feet. The robots pick containers off the shelving — transporting up to 8 at any given time for maximum order-batching efficiency — and deliver them to human-operated workstations.

Skechers’ HaiPick System contains 8 ergonomic workstations where operators receive clear instructions on a screen of the product and quantity to be picked to fulfill an order. The product is then scanned, and the system confirms order accuracy before the operator can proceed to the following order.

The HaiPick System is a vital part of the operational success in Skechers’ new distribution facility, helping Skechers maintain the high level of service and satisfaction their customers enjoy as they continue to grow.

“All automation projects have their challenges, but the Hai team has been a very good partner in maintaining a positive, can-do attitude and remaining committed to doing the right thing for the customer by delivering on their design,” said Sophie Houtmeyers, Vice President of Distribution Operations at Skechers, and Michael Pitt, MHE Solutions. “The Hai ACR system facilitated creative application to maximize both utilization of the warehouse floor space and hard-to-reach vertical storage space in a challenging Japanese warehousing design caused by strict fire codes. It has additionally provided productivity gains that are key to the growth of Skechers in the Japan market.”

“We are honored to help Skechers elevate the operations in their new facility and be a key part in the facility’s ability to quickly reach their customers,” said Brian Reinhart, Chief Revenue Officer at Hai Robotics U.S.A. “We are grateful for the trust that MHE and Skechers have placed in us and thrilled with the success seen so far. We will continue to work closely with MHE Solutions and Skechers to further support their warehouse automation journey and help them go above and beyond in their operational efficiency goals.”

About Hai Robotics
Hai Robotics is a leading global provider of Automated Storage and Retrieval Systems (ASRS) committed to elevating the world’s access to inventory through intelligent, fast, efficient warehouse automation that is more accessible to all facilities.

Their award-winning equipment drives highly flexible ASRS constructed of standard racking and almost any container. Hai Robotics’ solutions maximize vertical storage up to 32+ feet, reduce storage footprints up to 75%, increase workflow efficiency gains up to 4x, and improve order pick accuracy to 99.9%+.

Founded in 2016, Hai Robotics is trusted in 1,100+ projects across 40+ countries and supported by 8 offices globally. For more information, visit HaiRobotics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240220854625/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye